Purdue Pharma sues Amneal over OxyContin
Drugs company Purdue Pharma has filed a complaint against US-based generics company Amneal Pharmaceuticals for alleged patent infringement.
The case, which centres on Purdue’s OxyContin (oxycodone), was filed on Wednesday, March 1 at the US District Court for the District of Delaware.
OxyContin is used to treat moderate to severe pain that is expected to last for an extended period of time.
The dispute comes after Amneal filed an Abbreviated New Drug Application with the Food and Drug Administration seeking permission to market a generic version of the drug.
The patents involved in the case are US numbers 9,492,392; 9,492,393; and 9,522,919.
Purdue has asked the district court to enter a judgment that Amneal has infringed its patents, as well as a permanent injunction enjoining Amneal from bringing the generic product to market.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk